Impact of sarcopenic obesity on outcomes in patients undergoing living donor liver transplantation.
Kamo N., Kaido T., Hamaguchi Y., Okumura S., Kobayashi A., Shirai H.
Retrospective Study with a reported sample of 46 on Back & Spine, published in Clin Nutr (2018) — summary generated from the PubMed abstract.
Early human evidence such as case series or small samples is exploring possible benefits.
- Level A · Stronger Clinical Evidence
- Level B · Emerging clinical evidence with positive signals
- Level C · Early human research exploring benefits
- Level D · Scientific groundwork from lab and animal studies
- Emerging · Emerging topic under active research
This page is generated from the PubMed record. The Thai description is an automated summary of bibliographic fields and the abstract, not a full translation, and is not medical advice.
- Study type
- Retrospective Study
- Journal
- Clin Nutr (2018)
- Country
- England
- Reported sample size
- 46
- Source database
- PubMed
- PMID
- 30482562
- DOI
- 10.1016/j.clnu.2018.09.019
Abstract (original English)
Sarcopenia is known to be a poor prognostic factor after liver transplantation (LT). However, the significance of obesity in combination with sarcopenia (sarcopenic obesity) remains unclear. This study examined the impact of sarcopenic obesity on outcomes after living donor LT (LDLT). We retrospectively analyzed 277 adult patients who underwent LDLT at our center between January 2008 and June 2016. Body composition parameters including skeletal muscle mass index (SMI), intramuscular adipose tissue content (IMAC), visceral fat area (VFA), and visceral-to-subcutaneous adipose tissue area ratio (VSR) were evaluated by preoperative plain computed tomography imaging at the level of the third lumbar vertebra. This study defined sarcopenic obesity as a low SMI (male <40.31 cm 2 /m 2 ; female <30.88 cm 2 /m 2 ) with VFA ≥100 cm 2 or body mass index (BMI) ≥25 kg/m 2 . We examined outcomes among four groups: nonsarcopenic/nonobesity (NN), nonsarcopenic/obesity (NO), sarcopenic/nonobesity (SN), and sarcopenic/obesity (SO) groups. On the basis of VFA, 1/5-year overall survival (OS) rates in patients of SN (n = 46, 59%/46%, P < 0.001) and SO (n = 9, 56%/56%, P = 0.338) groups were lower than those in patients of the NN group (86%/80%). On the other hand, on the basis of BMI, 1/5-year OS rates in patients of SN (n = 49, 59%/52%, P < 0.001) and SO (n = 6, 50%/17%, P = 0.002) groups were signi
What this study does not prove
- • This study does not prove SVF is an approved treatment or a replacement for standard care.
- • Without an adequate control group, treatment effects cannot be separated from other factors.
Evidence level
Early human evidence such as case series or small samples is exploring possible benefits.
How we grade evidenceBrowse all related research
Filter the research library by this study's title keywords, author, or publication year.
Related research
- Level ASystematic ReviewEurope PMC
Stem cell therapy for degenerative disc disease: A systematic review of preclinical evidence, clinical translation, and future directions
Systematic Review on Back Pain, Disc Degeneration, published in N Am Spine Soc J (2026) — summary generated from the PubMed abstract.
- 2026
N Am Spine Soc J - Level AMeta-analysisEurope PMC
Association between platelet to lymphocyte ratio and the risk of vertebral fracture in patients with osteoporosis: a systematic review and meta-analysis
Meta-analysis on Back & Spine, published in Front Endocrinol (Lausanne) (2026) — summary generated from the PubMed abstract.
- 2026
Front Endocrinol (Lausanne) - Level ASystematic ReviewEurope PMC
The Role of Exosome-miRNA as Biomarkers of Alzheimer's Disease: A Systematic Review of Case-Control and Longitudinal Studies
Systematic Review with a reported sample of 3046 on Neuroinflammation, published in Actas Esp Psiquiatr (2026) — summary generated from the PubMed abstract.
- 2026
- n = 3046
Actas Esp Psiquiatr - Level AMeta-analysisEurope PMC
Platelet-Rich Plasma vs. Mesenchymal Stem Cells for Lumbar Disc Degeneration: A Systematic Review and Meta-Analysis
Meta-analysis on Disc Degeneration, published in Int J Mol Sci (2026) — summary generated from the PubMed abstract.
- 2026
Int J Mol Sci - Level ASystematic ReviewPubMed
Host immune determinants of stromal vascular fraction graft survival: Toward a concept of SVF therapy resistance - A systematic narrative review.
Systematic Review on Spinal Cord Injury, Chronic Inflammation, Immune Modulation, published in Cell Transplant (2026) — summary generated from the PubMed abstract.
- 2026
Cell Transplant - Level AMeta-analysisPubMed
Stem cell-derived exosome treatment for acute spinal cord injury: a systematic review and meta-analysis based on preclinical evidence.
Meta-analysis on Spinal Cord Injury, published in Front Neurol (2025) — summary generated from the PubMed abstract.
- 2025
Front Neurol